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ABStrAct                        It has recently been recognized that ascorbate-reducible cytochrome b561 (Cyt-
b561) proteins constitute a well-distinguished protein family amongst the two-heme containing 
b-type cytochromes, ubiquitously present in animals and plants. Of the six isoforms that have 
been identified in mammals, three isoformes (called CGCytb, DCytb, and LCytb) have been cloned 
and expressed in yeast and/or bacterial cells. The recombinant proteins have been characterized 
in some detail. A particular gene product of the 3p21.3 (human) and 9F1 (mouse) chromosomal 
region, a so-called tumor supressor protein (101F6, TSP10), was identified as a Cyt-b561 protein 
by sequence homology. We have cloned and expressed the mouse tumor supressor Cyt-b561 
protein (TSCytb) in yeast (Saccharomyces serevisiae), without and with a His6-tag on either the 
N- or the C-terminus. The C-terminal His6-tagged recombinant protein was purified on Ni-NTA 
His•Bind resin to almost homogeneity. Using optical spectroscopy we show that TSCytb is in-
deed an ASC-reducible cytochrome b561 protein and that ASC-reducibility is not affected by 
the presence of a His6-tag on the C-terminus. Minor differences in the properties of TSCytb and 
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b-Type cytochromes are metallo proteins containing one or 
more iron:protoporphyrine-IX complexes as a chromophore. 
A recently discovered group of b-type cytochromes, called cy-
tochromes b561 (Cyts-b561), consists of (i) ascorbate(ASC)-
reducible, (ii) trans-membrane proteins with six trans-mem-
brane helices, which (iii) have two heme b centers (iv) coor-
dinated in a particular way by four well-conserved histidine 
residues to four consecutive trans-membrane α-helices 
(Bashtovyy et al. 2003; Tsubaki et al. 2005). The two heme 
b prosthetic groups, with different redox potential values, 
reside on opposite sides of the trans-membrane proteins 
making them ideal for serving as trans-membrane electron 
transporters. The Cytb-561 that was discovered first is the 
chromaffin granule Cyt-b561 that had already been known as 
chromomembrin B (Flatmark and Terland 1971; Silsand and 
Flatmark 1974; Apps et al. 1980). This protein functions as an 
electron transporter providing electrons from cytosolic ASC 
through the chromaffin granule membrane to intravesicular 
dopamine β-hydroxylase (Njus and Kelley 1993; Njus et al. 
2001). After resolving the full genomic sequence of a large 
variety of organisms, and improving in silico techniques for 
comparing gene and protein sequences, numerous proteins 
were identified similar to CGCytb in various organisms, 
including invertebrates, vertebrates, and plants (Verelst and 
Asard 2003; Tsubaki et al. 2005). Three mammalian and one 
plant Cyts-b561, namely the chromaffin granule Cyt-b561 
(CGCytb), the duodenal Cyt-b561 (DCytb; [McKie et al. 
2001]), the lysosomal Cyt-b561 (LCytb; [Zhang et al. 2006]), 
and the tonoplast Cyt-b561 (TCytb; [Griesen et al. 2004]), 
showed ASC-dependent trans-membrane ferrireductase 
activity when expressed in yeast cells (Su and Asard 2006; 
Bérczi et al. 2007). However, CGCytb is participating in 
ASC regeneration in chromaffin granules (Kent and Fleming 
1987; Njus and Kelley 1993) while another isoform, DCytb, 
appears to be involved in extracellular recycling of ASC of 
human erythrocytes (Su et al. 2006). Only DCytb has already 
been shown to be involved in iron metabolism (McKie et al. 
2001; Vargas et al. 2003). The biological function of LCytb 
and TCytb has not yet been elucidated. 
At the level of genomic and predicted protein sequences, a 
human tumor supressor protein (the 101F6 gene product) has 
been identified as putative member of the Cyts-b561 (Lerman 
and Minna 2000; Ponting 2001). The mouse homologue was 
also discovered, sequenced, and shown to be 85% and 95% 
identical with the human sequences on the cDNA and protein 
sequence level, respectively (Lerman and Minna 2000). Both 
proteins have (i) 6 trans-membrane α-helices with (ii) 222 
residues, (iii) the N- and C-termini in the cytoplasm, and (iv) 
4 well-conserved histidine residues for binding two heme 
b prosthetic groups. 101F6 mRNA is widely expressed in 
animal tissues, and the mouse mRNA is especially abundant 
in liver, kidney, and lung (Mizutani et al. 2007), while the 
human protein is most abundant in liver, placenta, and lung 
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(Lerman and Minna 2000). Expression of wild-type101F6 
in tumor cells significantly inhibited cell growth and intra-
tumoral injection of recombinant adenovirus-101F6 gene 
vectors, as well as systemic administration of protamine-
complexed adenovirus-101F6 gene vectors, significantly 
suppressed tumor xenografts growth (Ji et al. 2002). Ohtani 
et al. (2007) have recently found that nanoparticle-mediated 
101F6 gene transfer and a subpharmacologic concentration 
of ASC synergistically and selectively inhibited tumor cell 
growth by caspase-independent apoptosis and autophagy 
in vitro and in vivo. C terminal myc-tagged mouse 101F6 
protein has been expressed in Chinese hamster ovary (CHO) 
cells and immunofluorescence microscopy was used to lo-
calize the recombinant proteins; they were found in small 
vesicles, including endosomes and endoplasmic reticulum 
of the perinuclear region (Mizutani et al. 2007). It was also 
shown that CHO cells expressing the C terminal myc-tagged 
mouse 101F6 protein showed higher ferric ion and azo-dye 
reduction level than the control CHO cells. Mizutani et al. 
(2007) concluded that mouse 101F6 proteins played roles in 
the ferrireduction via a yet unresolved mechanism. 
In this paper we report on the cloning and expression of 
the mouse 101F6 gene in a yeast expression system, both 
with and without a His
6
-tag on either the C-terminus or the 
N-terminus. It is shown that the recombinant mouse tumor 
suppressor protein is indeed an ASC-reducible b-type cyto-
chrome and the His
6




The protease inhibitor cocktail tablet „cOmplete”, NBT 
(Nitro blue tetrazolium chloride), BCIP (5-Bromo-4-chloro-
3-indolyl phosphate, toluidine salt) in 67% DMSO (v/v), were 
from Roche (Mannheim, Germany); Sucrose monolaurate 
(SML) was from Dojindo (Tokyo, Japan); Ni-NTA His•Bind 
Resin was from Novagen (Darmstadt, Germany); DifcoTM 
yeast nitrogen base w/o amino acids was from BD (Sparks, 
MD, USA); other chemicals were analytical grade and from 
Acros (Geel, Belgium) or Fluka (Buchs, Switzerland) or 
Serva (Heidelberg, Germany).   
Molecular biology works
For expression of untagged proteins, the cDNA of mouse 
TSCytb (the sequence corresponds to GenBank protein 
entry, NP_062694; see Fig. 1) was amplified from mouse 
whole brain RNA and was cloned into a pESC-His expres-
sion vector (Stratagene, La Jolla. CA), downstream of the 
GAL10 galactose-inducible promoter, using EcoRI and SpeI 
restriction sites. Yeast cells (Saccharomyces cerevisiae, strain 
YPH499: ura3-52 lys2-801amberade2-101ochre trp1-Δ63 his3-
Δ200 leu2-Δ1) were transformed and grown according to the 
manufacturer’s instructions (Stratagene). 
For expression of His
6
-tagged proteins, a standard PCR 
method was used to amplify the gene for TSCytb from mouse 
Figure 1. Multiple alignment of bovine (Bos taurus, Bt) CGCytb, mouse (Mus musculus, Mm) TSCytb, and human (Homo sapiens, Hs) TSCytb using 
Clustal W (v. 2.0.1) software (http://www.ebi.ac.uk/Tools/clustalw2/index.html). Predicted trans-membrane segments are bold faced, underlined, 
and obtained by using HMMTOP (http://www.enzim.hu/hmmtop/). The highly conserved His residues binding the two hemes are labelled in 
pairs with stars (* and +). Gray triangles (▲) show the 10 amino acid residues where the mouse and human TSCytb are different. 
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whole brain RNA. Primers were designed to generate EcoRI 
and SpeI sites for cloning into the pESC-His expression vec-
tor (Stratagene, La Jolla, CA), downstream of the GAL10 
galactose-inducible promoter, and with a His
6
 tag either on 
the C- or the N-terminus. Four oligonucleotide primers were 











First, the PCR-amplified products were inserted into 
pGEM-T Easy vectors (Promega Corp., Madison, WI, USA), 
and the resulting vectors were transformed into E. coli DH5α 
cells using calcium chloride competent cells and the Nucleo-
Spin Plasmid QuickPure kit (Macherey-Nagel GmbH & Co., 
Düren, Germany). The pGEM-T Easy vectors with the inserts 
were isolated with the NucleoSpin Plasmid QuickPure kit and 
inserted into empty pESC-His vectors by using the restriction 
enzymes EcoRI and SpeI. The integrity of the His
6
-tagged 
TSCytb/pESC-His vectors was confirmed by restriction 
digestion and DNA sequencing. Finally, pESC-His verctors 
were transformed into competent yeast cells (Saccharomyces 
cerevisiae, strain YPH499, ura3-52 lys2-801amberade2-101ochre 
trp1-Δ63 his3-Δ200 leu2-Δ1) and the transformed cells were 
tested on SD-dropout medium (http://www.stratagene.com/
manuals/217451.pdf) where the lack of histidine was the 
selective factor. For induction of protein expression and pro-
duction of the recombinant proteins, overnight cultures were 
grown in SD-dropout medium, transferred to SG-dropout 
medium (http://www.stratagene.com/manuals/217451.pdf) 
and grown for 24-28 hours. 
yeast membrane preparation 
Cells grown as 2 x 350 ml cultures in SG-His medium were 
collected by low-speed centrifugation (at 4,000 g
max
 and 
10°C for 10 min) when the OD
600
(d=1cm) reached a value of 
0.8 ± 0.05. Collected cells were washed once with ice cold 




, 100 mM NaCl, pH 7) and 
pelleted as above. Washed cells were resuspended in 15 ml 
of ice cold homogenization buffer (50 mM MES-KOH, pH 
7.0, 5 mM EDTA, 150 mM KCl, 150 mM sucrose) supple-
mented with freshly added 0.1% (w/v) Na-ASC and protease 
inhibitors (1 mM PMSF and aprotinin, pepstatin, leupeptin, 
antipain, chymostatin in the form of 1 dissolved cOmplete 
tablet). Cells were broken in a Bead Beater (Biospec Prod-
ucts, Bartlesville, OK, USA) with four 30 s cycles, with 2 
min cooling intervals, using 0.5 mm glass beads. Beads were 
rinsed with 35 ml of ice cold homogenization buffer. The 
homogenate (50 ml) was centrifuged at 4,000 g
max
 and 5°C 
for 10 min to remove unlysed cells and cell debris. A yeast 
microsomal membrane (YM) fraction was obtained after 
centrifugation of the 4,000 g
max
 supernatant at 75,000 g
max
 
and 4°C for 60 min (Sorvall Discovery 90 ultracentrifuge and 
T-647.5 rotor; Sorvall Products, L.P., Newtown, CT, USA). 
After centrifugation, the pellet was resuspended in 20 mM 
phosphate buffer, pH 7, and the membrane vesicles were 
stripped as before (Bérczi et al. 2005). Stripped microsomal 
membrane (SYM) vesicles were resuspended in phosphate 




, 10% (w/v) glycerol, pH 7), and 
stored at −80°C until use. 
Sucrose density gradient fractionation
For membrane fractionation, after stripping and final centrifu-
gation, SYM vesicles were resuspended in 4 ml of MES-KOH 
buffer (50 mM MES, 10% (w/v) sucrose, pH 7) and layered 
on the top of a discontinuous sucrose density gradient made 
of 2 ml of 70% (w/v), 10 ml of 45% (w/v), 9 ml of 32% 
(w/v), and 8 ml of 20% (w/v) sucrose solutions in 50 mM 
MES-KOH buffer, pH 7. Fractionation was by centrifuga-
tion in an AH-629 swing-out rotor (Sorvall Products, L.P., 
Newtown, CT, USA) in a Discovery 90 ultracentrifuge at 
28,900 rpm (g
max
=150,000g), at 5ºC for 3 hours. The cloudy 
bands at the interfaces were collected with a Pasteur pipette, 
diluted ten-fold by 20 mM MES-KOH, pH 7, and pelleted 
by centrifugation (Sorvall T-647.5 rotor and Discovery 90 
ultracentrifuge) at 75,000 g
max
 and 4°C for 90 min. After 





, pH 7, containing 10% (w/v) glycerol), and 
stored at −80°C until use.
Protein solubilization and purification by His6-
tag affinity chromatography





, 10% (w/v) glycerol, pH 7, were thawn and proteins 
were solubilized by sucrose monolaurate (SML) at 1 mg ml−1 
protein concentration and 3:1 (w/w) detergent:protein ratio. 
The mixture was incubated on a rocker at 5°C for 90 min. 
Insoluble material was pelleted by high-speed centrifugation 
(T-647.5 rotor and Sorvall Discovery 90 ultracentrifuge) at 
75,000 g
max
 and 5°C for 60 min. The supernatant containing 
the detergent-solubilized proteins was supplemented with 
500 mM NaCl and 10 mM imidazole, the pH was adjusted 
to 7.8 and then mixed with 1 ml (bed volume) of Ni-NTA 
His•Bind resin (Novagen, Madison, WI, USA) that had been 




, pH 7.8, containing 
10% (w/v) glycerol, 1%(w/v) SML, 500 mM NaCl and 10 
mM imidazole. The affinity resin was incubated with the 
solubilized proteins at room temperature for 30 min. After 
incubation, the Ni-NTA His•Bind resin with bound proteins 
was collected in a 10-ml disposable column and washed 3 
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, pH 7.8, con-
taining 10% (w/v) glycerol, 0.3% (w/v) SML, 500 mM NaCl 
and 10 mM imidazole. His
6
-tagged proteins were eluted with 




, pH 7.0, 
containing 10% (w/v) glycerol, 0.3 %(w/v) SML, 150 mM 
NaCl and 250 mM imidazole). The affinity resin was further 
washed with 10 bed volumes of elution buffer while the eluate 
was concentrated by centrifugation using Centricon-YM100 
centrifugal filter unit (Millipore, Bedford, MA, USA) and 
desalted by using a PD-10 desalting column (Amersham 
Biosciences, Uppsala, Sweden). The desalted fraction was 
concentrated again by centrifugation using Centricon-YM100 
centrifugal filter units and the concentrated fraction was 




, 10% (w/v) glycerol, 0.3 % (w/v) 
SML, pH 7, at −80°C until use.
Absorption spectroscopy
Absorption spectra with SYM vesicles were recorded in 
dual wavelength mode between 500 nm and 600 nm (with 
601 nm as reference wavelength) while absorption spectra 
with the solubilized protein fractions were recorded in split 
beam mode between 350 nm and 650 nm (with buffer as ref-
erence) by using an OLIS-updated SLM-Aminco DW2000 
spectrophotometer (OLIS Co., Bogart, GA, USA) with 2 nm 
slit-width at room temperature and under continuous stirring. 





]) and the fully oxidized spectrum 
was recorded. Then ASC was added and the ASC-reduced 
spectrum was recorded. Finally Na-dithionite (DTH) was 
added (2-5 mM final concentration) and the DTH-reduced 
spectrum was obtained at room temperature. When improve-
ment of the signal to noise ratio was needed, multiple scans 
were averaged. Amount of cytochromes was calculated from 
the reduced-minus-oxidized difference spectra by using a 
millimolar extinction coefficient of ε
561nm
=30 mM−1∙cm−1 
(Tsubaki et al. 1997; Liu et al. 2005). 
Gel electrophoresis and Western blotting 
Protein content of samples (both of membranes and of deter-
gent micelles) was estimated by the modified Lowry method 
(Markwell et al. 1978) with deoxycholate as detergent and 
BSA as standard. 
Proteins were resolved by SDS-PAGE (Laemmli 1970) 
by using 4.5% (stacking) and 12% (running) polyacrylamide 
gels. Samples were not heated or boiled prior to loading on 
gels because harsh temperature treatment is known to cause 
the highly hydrophobic integral membrane proteins to ag-
gregate, preventing them from penetrating into the 12% run-
ning gel (Duong and Fleming 1982; Thomas and McNamee 
1990). Low Range and Kaleidoscope Prestained molecular 
weight standards (BioRad, Hercules, CA, USA) were used 
for the Coomassie staining and for the Western blotting, 
respectively. 
For protein visualization, gels were stained with 0.2% 
(w/v) Coomassie Brillant Blue R-250 in 50% (v/v) methanol, 
10% (v/v) acetic acid for 2 hours and destained in 40% (v/v) 
methanol, 10% (v/v) acetic acid in three 30 min steps. Finally 
the destained gels were rinsed in 40% (v/v) methanol, 10% 
(v/v) acetic acid, 5% (v/v) glycerol and dried between two 
layers of wet cellophane sheets at room temperature. 
For visualization and identification of His
6
-tagged TSCytb, 
gels were transferred onto polyvinylidene difluoride mem-
branes (PVDF) with a Mini Trans-Blot Electrophoretic Trans-
fer Cell (both from BioRad, Hercules, CA, USA) in 25 mM 
Tris, 192 mM glycine, 20% (v/v) methanol. A mouse mono-
clonal antibody to the 6X-His tag (Abcam, Cambridge, UK) 
was used to detect the recombinant proteins. Protein-antibody 
complexes were visualized by alkaline phosphatase-coupled 
rabbit-anti-mouse secondary antibodies (Pierce, Product #: 
31332, Rockford, IL, USA) after reacting with NBT/BCIP 
(http://www.cshprotocols.org/cgi/content/full/2007/15/pdb.
rec11089).




The YPH499 yeast cell line and pESC-His vector has already 
been successfully used for cloning His
6
-tagged Cytbs-561 
(Griesen et al. 2004; Bérczi et al. 2005; Zhang et al. 2006) 
and the expression system provided recombinant CGCytb 
with physico-chemical properties similar to the native pro-
Figure 2. Coomassie Brillant Blue R-250 stained (A) and Western blotted 
(B) SDS-PAGE picture of YM fractions containing C-terminal (lane 1) or 
N-terminal (lane 3) His6-tagged TSCytb. Molecular mass standards are 
on lanes 2. 25 µg (A) and 10 µg (B) of proteins were loaded.
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tein (Bérczi et al. 2005). Other yeast cell lines and vectors 
were also successfully employed in high yield expression of 
mammalian Cyts-b561 (Liu et al. 2005; Su and Asard 2006). 
It was therefore plausible to use a yeast expression system for 
producing appropriate amounts of a novel recombinant Cytb-
561 and establishing the basic physico-chemical properties of 
the expressed protein. N-terminal or C-terminal His
6
-tagged 
TSCytb was expressed and the YM fraction was used to 
check the expression levels. Figure 2 shows that the con-
centration of the N-terminal His
6
-tagged TSCytb in the YM 
fraction was considerably lower than that of the C-terminal 
His
6
-tagged TSCytb (hereafter (H
6
C)TSCytb). This result 
is in agreement with former observations obtained with the 
His
6
-tagged CGCytb and TCytb proteins (data not published), 
although the reason of the difference in expression levels is 
not yet known. 
When mammalian or plant Cyts-b561 were expressed 
in ferrireductase-deficient yeast cells (Δfre1Δfre2 mutant 
lines), the capacity of these cells to reduce extracellular 
ferric-compounds was restored (Su and Asard 2006; Bérczi et 
al. 2007). These results were indirect proof that the recombi-
nant Cyts-b561 was at least in part, targeted to the yeast cell 
plasma membrane.
Continuous sucrose density gradient fractionation of YM 
vesicles revealed that plasma membrane vesicles assembled 
at position of rather high sucrose concentrations (>45% 
(w/v); Roberg et al. 1997). When the distribution of (H
6
C)
TSCytb in the SYM fraction was studied by discontinuous 
sucrose density gradient centrifugation and Western blotting, 
(H
6
C)TSCytb was almost evenly distributed in membrane 
fractions at all sucrose density steps (Fig. 3). In fact, the low-
est concentration of TSCytb appears at the highest sucrose 
Figure 3. Coomassie Brillant Blue R-250 stained (top) and Western 
blotted (bottom) SDS-PAGE picture of SYM fractions containing 
(H6C)TSCytb. Lanes are: 1 for molecular mass standards, 2 for SYM, 
3 for SYM at the 10%/20% sucrose step interface, 4 for SYM at the 
20%/32% sucrose step interface, 5 for SYM at the 32%/45% sucrose 
step interface, 6 for SYM at the 45%/70% sucrose step interface, and 
7 for BSA and cytochrome c. 18 µg (top) and 2 µg (bottom) of protein-
were loaded in lanes 2 through 6. a - 66.2 kDa for BSA; b - 12.4 kDa 
for horse cytochrome c. 
Figure 4. Coomassie Brillant Blue R-250 stained (A) and Western blot-
ted (B) SDS-PAGE picture of highly purified (H6C)TSCytb after PD-10 




concentration step employed, i.e. the location at which the 
yeast plasma membrane is expected. Mizutani et al. (2007) 
showed that myc-tagged TSCytb was localized in small 
vesicles, including endosomes and endoplasmic reticulum of 
the perinuclear region, using an immunofluorescent staining 
technique. Therefore, the localization of (H
6
C)TSCytb in the 
lighter SYM fractions was not a surprise. However, the rather 
homogeneous distribution of (H
6
C)TSCytb in different and 
lighter populations of yeast membrane vesicles appears to be 
different from the mostly yeast plasma membrane localization 
of the other three recombinant mouse Cyts-b561 expressed in 
yeast. This result pointed out that enrichment of a membrane 
fraction containing (H
6
C)TSCytb by differential and/or den-
sity gradient centrifugation before membrane solubilization 
could not be achieved. 
As the protein balance sheet shows (Table 1), stripping 
of the YM vesicles resulted in the loss of about 30% of the 
proteins. Treatment of the SYM vesicles with the nonionic 
detergent SML, at a detergent:protein ratio of 3:1 (w/w) and 
1 mg/ml protein concentration, resulted in solubilization of 
about 45% of the membrane proteins. When the solubilized 
fraction was concentrated by using a membrane filter with 
100 kDa cut-off value, >90% of solubilized proteins were 
retained. About 75% of the solubilized and concentrated 
proteins did not bind the Ni-NTA His•Bind resin (Table 1, 
unbound fraction), however, only about 8% of the bound 
proteins were strongly associated with the resin, and eluted 
using the elution buffer (Table 1, (H
6
C)TSCytb fraction). In 
order to exchange the high salt and imidazole-containing 
elution buffer to a widely-used phosphate buffer for storage 
of (H
6
C)TSCytb, the coral red fraction was passed through 
a PD-10 column and then concentrated. Figure 4 shows that 
the final (H
6
C)TSCytb fraction contained mostly His
6
-tagged 
TSCytb, but small amounts of contaminating proteins can be 
seen on the gel. Even the fraction of proteins, which did not 
enter the separation gel, contained (H
6
C)TSCytb, according 
to the Western blot staining. After solubilization, protein con-
centration, affinity chromatography, PD-10 chromatography, 
and a second protein concentration step, the ASC-reducible 
TSCytb recovery was between 40 and 50% which is in good 
agreement with former results (Bérczi et al. 2007). 
Spectroscopy
TSCytb was classified as member of the Cyts-b561 on the 
basis of its sequence homology and predicted structural 
similarity to bovine CGCytb (Ponting 2001; Tsubaki et al. 
2005; Su and Asard 2006). Figure 5 shows that TSCytb is 
Fraction Total protein, mg ASC-reduced TSCytb
pmol∙mg−1
YM 198 ± 47 n.m.
SYM 143 ± 31 77± 18
100P 72 ± 15 n.m.
100S 60 ± 13 n.m.
Filtrate 5.7 ± 1.4v n.m.
Unbound 46 ± 7 n.m.
(H6C)TSCytb 1.2 ± 0.3 3850 ± 341 
(§)
Table 1. Protein balance sheet. For each His6-tag affinity chro-
matography step, 100S fractions from two independent experi-
ments were used; for each solubilization step, SYM fractions from 
two independent membrane preparations were used; and at 
each membrane preparation, 700 ml of yeast cell cultures with 
OD600(d=1 cm) of 0.8±0.05 was used. Results are the means ± s.d. 
from 8 independent His6-tag affinity chromatography steps except 
for the last value (§) which is mean ± s.d. from 4 independent 
purifications. YM – yeast microsomal membranes, SYM – stripped 
yeast microsomal membranes, 100P – unsolubilized membranes 
(the 100,000 gmax pellet after the solubilization step), 100S – the 
concentrated protein fraction after solubilization, Filtrate – solu-
bilized protein fraction which passed through the 100,000 kDa 
membrane filter, Unbound – solubilized proteins unbound to the 
Ni-NTA His•Bind Resin, (H6C)TSCytb – concentrated His6-tagged 
TSCytb proteins eluted from the Ni-NTA His•Bind Resin. n.m. is 
for “not measured”. 
Figure 5. ASC-reduced (a) and dithionite-reduced (d) minus oxidized 
difference spectra of SYM fraction containing untagged (A) and 
His6-tagged (B) TSCytb. 7.5 mg∙ml
−1 was the protein concentration in 
both cases. 
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indeed a membrane-associated b-type cytochrome, with an 
α-band absorbance maximum around 560 nm. TSCytb is also 
ASC reducible which is the basic property of Cyts-b561. It 
is evident that the presence of a His
6
-tag on the C terminus 
does not affect the ASC reducibility of the protein. However, 
the specific ASC-reducible cytochrome b content of SYM 
vesicles (between 50 and100 pmol∙mg−1 protein), tested 
with 25 mM ASC, was much lower than that obtained with 
other Cyts-b561 expressed in yeast (CGCytb: about 1500 
pmol.mg−1 [Bérczi et al. 2005]; TCytb: about 400 pmol.mg−1 
[Bérczi et al. 2007]; LCytb: about 150 pmol.mg−1 [Zhang et 
al. 2006]). It is also evident that the untagged and His
6
-tagged 
protein in the SYM fraction had considerably lower ASC re-
ducibility, as compared to dithionate reducibility, than either 
CGCytb or TCytb (see later). 
Recombinant CGCytb and TCytb reached saturation in 
ASC-reducibility at 25 mM ASC (Lakshminarasimhan et 
al. 2006; Bérczi and Asard 2006). However, this was not 
the case with TSCytb. As seen in Figure 6, ASC-reduction 
continued to increase even at 75 mM ASC. It is evident that 
the ASC-dependent reduction of TSCytb cannot be described 
by a single binding or affinity site, as it was also evident with 
CGCytb and TCytb (Lakshminarasimhan et al. 2006; Bérczi 
and Asard 2006). However, the two binding or affinity site 
model, which could explain the ASC-dependent reduction of 
CGCytb and TCytb, cannot be unambiguously employed for 
TSCytb due to the uncertainty of experimental points; as seen 
in Figure 6, both a “two binding site model” and a “logistic 
model” provide fitted curve with r2>0.98. 
Finally, maximal reduction of b-type cytochromes can be 
obtained in the presence of 2-5 mM dithionite. The maximal 
ASC-reduction of CGCytb and TCytb is about 75-80% of 
the dithionite-reduced maximal reduction value (Bérczi et al. 
2005, 2007). As Figure 7 shows, reduction of highly purified 
TSCytb at 50 mM ASC concentration is only about 50% of 
that at 5 mM dithionite concentration. This is particularly 
well seen in the Soret band of spectra where the disappear-
ance of the absorption peak at 415 nm in the fully oxidized 
spectrum is parallel with the appearance of the γ-peak at 428 
nm in the fully reduced spectrum through an isosbestic point 
at 421 nm. 
The specific cytochrome b content of the highly purified 
(H
6
C)TSCytb fraction was about 4 nmol∙mg−1 protein (Table 
1). This value is again lower than (one third of) those values 





C)TCytb (Bérczi et al. 2005, 2007) but the 
difference is smaller than that observed at the level of SYM 
vesicles (see above). One reason for the difference between 
the specific TSCytb content in the SYM fraction and highly 
purified protein fraction could lie in different expression lev-
els of the different recombinant proteins in yeast. However, 
another source for the observed differences could be that 
in all calculations we use the molar extinction coefficient 
established for the bovine CGCytb at 561 nm and with di-
thionite as the reducing agent. It is possible, on the basis of 
differences in the primary structure of Cyts-b561 (see Fig. 
1), that different Cyts-b561 have different molar extinction 
coefficients. Furthermore, detailed reduction mechanisms 
with ASC and/or dithionite have not yet been established. It is 
well known that the presence of dithionite in solutions causes 
Figure 6. ASC-dependent reduction of highly purified (H6C)TSCytb. 
Protein concentration was 0.4 mg∙ml−1. Y axes are values obtained by 
integration between 542 and 569 nm of the (α+β)-peak in the reduced 
minus oxidized difference spectrum. Experimental points cannot be 
fitted by a single ASC-binding or -affinity site model (Hyperbole fit, 
dash line, r2<0.95). However, both a two ASC-binding or -affinity site 
model (Dihyperbole fit, solid line) and a „logistic-type” model (Logis-
tic fit, dash-dot-dot line) gave appropriate fits with similar r2 values 
(>0.98). Mathematical analysis was with OriginPro 7.5 Data Analysis 
and Graphing Software. 
Figure 7. Oxidized, ASC-reduced and dithionite-reduced spectra of 





oxygen depletion. Oxygen depletion is transient, depending 
on the starting concentration of dithionite and contact of the 
solution with air (that is mostly the case in spectrophotometer 
cuvettes). Since the role of oxygen as an oxidant to Cyts-b561 
is not yet clear, it may affect the final reduction levels of the 
protein when any reducing agent is added. Taken together, 
we conclude that a reliable quantitative comparison between 
the properties of different Cyts-b561 will be possible only 
after establishing the proper molar extinction coefficient for 
each protein and the role of disolved oxygen for the reduction 
mechanism(s) of Cyts-b561. 
comparison of tScytb to cGcytb and tcytb
In this paper, we have reported the expression of the His
6
-
tagged recombinant mouse TSCytb in the very same yeast 
expression system previously used for mouse CGCytb, 
DCytb, LCytb, and TCytb from Arabidopsis thaliana. It is 
shown that (i) TSCytb is an ASC-reducible b-type cytochrome 
but its sensitivity to ASC is considerably lower than that ob-
served with CGCytb and TCytb, (ii) the specific content of 
TSCytb is lower than those of CGCytb and TCytb in the very 
same SYM fractions, (iii) the ASC-reducibility of TSCytb is 
lower than that of CGCytb and TCytb when compared to the 
maximal reduction of these Cyts-b561 by dithionite. These 
minor differences in the basic ASC-reducible properties 
might be explained by detailed sequence comparison of these 
proteins. Indeed, it was found that CGCytb, DCytb, LCytb, 
and even TCytb are evolutionary much closer to each other 
than to TSCytb (Tsubaki et al. 2005; Su and Asard 2006), 
supporting that these proteins might have little but important 
differences in structures which is manifested in different 
physico-chemical properties. 
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